Emerging Treatments in MG


Neurology experts provide an overview of emerging treatments in MG, highlighting biomarkers and new routes of administration.

This is a video synopsis/summary of a panel discussion involving James Howard, MD; Nicholas Silvestri, MD, FAAN; Tuan Vu, MD; Ali Habib, MD; and Beth Stein, MD.

The discussion revolves around the excitement in the landscape of myasthenia therapies. Various promising treatments are emerging, including publications on phase 1 and 2 results and upcoming phase 2 outcomes from multiple companies. Participants mention a plethora of developments, such as CAR-T therapy, complement inhibitors, B-cell therapies, and IL-6 therapies, leading to a potential future dilemma of selecting the most suitable treatment for each patient.

One major challenge highlighted is the lack of biomarkers to guide treatment decisions effectively. The conversation also delves into the convenience of self-administration methods, which could enhance patients' quality of life. The range of therapies, from upstream to downstream and from infrequent to frequent administration, adds to the excitement, albeit with the anticipation of a guideline nightmare due to the multitude of options.

The possibility of achieving tolerance through immune system reset is another intriguing topic, met with both skepticism and optimism among immunology experts. Overall, the panel expresses enthusiasm for the evolving landscape of myasthenia therapies, acknowledging the complexity and potential paradigm shifts in treatment approaches.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
© 2024 MJH Life Sciences

All rights reserved.